Organic Active Ingredients TRIZ Cases

Merging ALK and EGFR inhibitors delays drug resistance onset while enhancing anti-tumor efficacy in non-small cell lung cancer treatment.

Gapmer antisense oligonucleotides use non-bicyclic high-affinity wing nucleotides to maintain target RNA inhibition potency.

Pyridine-3-carboxylate compounds selectively activate neuronal Cav1.2 channels, reducing cardiovascular side effects while treating psychiatric disorders.

Dual oxazolidine cycles boost anthracycline cytotoxicity while preventing dimer formation, resolving low potency issues in ADC payloads.

Measuring ER stress marker levels predicts patient response to anti-cancer agents.

Administering dexamethasone prior to therapy prevents seizures and encephalopathy caused by CD3 binding domains.

Antibodies bind extracellular EGF domains of Notch2 and Notch3 receptors, blocking ligand interaction to inhibit tumor growth and angiogenesis.

Segmented antisense oligonucleotides degrade AR mRNA to overcome castrate-resistant prostate cancer treatment failure.

Substituted azole compounds inhibit cytochrome P450 enzymes, elevating retinoic acid levels to improve skin barrier function without retinoid side effects.

Optimized pH and excipients prevent aggregation in the MF-T-SPDB-DM4 formulation, ensuring long-term stability.

Elevating intracellular magnesium via magnesium threonate increases presynaptic terminal density and mitochondrial function while reducing release probability.

A paracetamol-based pharmaceutical preparation delivers targeted anti-HPV activity through synergistic adjuvant combinations.

Linking MCL-1 ligands to cereblon binders via a linker induces proteasomal degradation while reducing cardiac cytotoxicity.

Long-acting mirabegron palmitate parenteral formulations deliver sustained therapeutic levels via intramuscular injection.

Phenylboronic acid nanoparticles bind glucose in cancer tissue to enable simultaneous imaging and therapy, avoiding toxicity from traditional contrast agents.

Heterocyclic PGI2 receptor agonists reduce colitis severity and intestinal shrinkage while minimizing accumulated side effects from long-term steroid use.

Fused azadecalin compounds resolve conflicting affinity and specificity requirements by optimizing ring J substituents for precise receptor modulation.

Selective S1P5 solid forms improve CNS therapeutic reliability while minimizing cardiovascular side effects.

Anti-S100P monoclonal antibodies bind S100P protein to enable specific detection in biofluids.

Modifying substituent positions on the core structure reduces hERG binding affinity to improve safety without compromising Wee1 inhibition efficacy.

Tolerizing liposomes embedded in a polymer matrix deliver antigens locally to restore lasting immunological tolerance without global suppression.

Substituted tricyclic compounds act as GPR40 agonists to treat Type 2 diabetes without hypoglycemia or weight gain risks.

Seedless synthesis of lysine acetylsalicylate glycine achieves high yields and controlled particle sizes without contamination risks from added seeds.

MOR202 binds CD38 antigens on malignant plasma cells, depleting tumor populations to extend progression-free survival and overcome low remission rates.

Lipid particles hold nucleic acids via electrostatic interactions, resolving the trade-off between delivery stability and cytotoxicity.

Segmenting incompatible active ingredients prevents discoloration during storage while maintaining therapeutic efficacy.

Combining Lactobacillus rhamnosus HN001 with prebiotics resolves mixed probiotic efficacy by reducing allergic lung disease severity without prenatal risks.

Substituted 6,5-fused bicyclic heteroaryl compounds inhibit histone methyltransferase activity of EZH2.

Enzymes break down iso-malto oligosaccharides into shorter chains to stimulate lactobacilli and bifidobacteria growth.

Substituted aurone compounds deliver antitrypanosomal, antifungal, and immunomodulatory effects through covalent coumaranone-aldehyde synthesis.

Calebin A attenuates high fat diet-induced hepatic steatosis by modulating PPARγ signaling and reducing pro-inflammatory cytokines.

SCD1 polypeptide inhibitors constrain B cell activation to reduce autoimmune disease severity.

Removing polar groups from macrocyclic inhibitors improves oral bioavailability while maintaining therapeutic efficacy against thromboembolic disorders.

Polylysine binds furin protease to block spike protein cleavage, reducing viral load and improving recovery rates.

Oxysterol-bone targeting agents stimulate bone formation via Hedgehog signaling activation, addressing low bioavailability and side effects of bisphosphonates.

Culturing stem cells with immunoregulatory factors to produce extracellular vesicles enriched in anti-inflammatory microRNAs.

Thermoreversible chitosan composites create durable teat seals, preventing mastitis and cheese defects.

Labrasol and PEG 300 solubilize hydrophobic GMC1 to overcome poor water solubility for effective prostate cancer treatment.

Selective heteroaryl-pyrimidinone PDE2 inhibitors improve cognitive function while reducing metabolic and cardiac side effects of current antipsychotics.

Solid oral dosage forms release testosterone undecanoate using a carrier to avoid lipid instability and liver harm.

Segmented CTI-CTI dimers expand cancer treatment profiles by enhancing ADC reliability and potency.

Antioxidant mediators prevent oxidative degradation of buprenorphine, eliminating cold chain storage requirements for extended shelf life.

Benzimidazole derivatives modify chemical structures to enhance binding affinity, addressing the commercial viability gap in approved FLAP inhibitors.

Administering ganaxolone at lower doses concurrently with intravenous anesthesia prevents seizure recurrence when weaning off anesthetics.

Neutrophil granulocytes transport drugs to inflamed tissues, overcoming high interstitial pressure and reducing systemic toxicity.

Compounds targeting the MRGPRX2 receptor inhibit mast cell degranulation, treating antihistamine-refractory chronic urticaria and pruritus.

A monolithic tablet uses a swellable hydrophilic matrix and pH-independent gelling polymer for controlled drug release.

Controlled crystallization yields stable Form B, resolving polymorphism contradictions to ensure manufacturing reliability and reduced impurities.

Moist heat sterilization of the polymer phase preserves viscosity stability while filtration of the API phase ensures sterility.

Novel 5-(heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds bind to the 5-HT6 receptor.

Structural modifications create versatile derivatives that manage substance abuse by reducing agonist activity without losing therapeutic effectiveness.

CPT-1 inhibitors prevent neural delipidation by blocking fatty acid transport, addressing underlying causes of neurological disorders.

Substituted N-phenylpyrimidin-2-amine analogs inhibit Axl kinase activity through targeted molecular binding.

Quaternary ammonium compounds reduce systemic side effects by achieving selective pulmonary receptor binding and extended duration of action.

Bicyclic compounds selectively inhibit JAK3 to treat ulcerative colitis while sparing beneficial cytokines and reducing systemic immunosuppression.

A pharmaceutical composition combines lidocaine, chondroitin sulfate, and hyaluronic acid to deliver rapid analgesic effects.

Senicapoc blocks KCa3.1 channels to reduce neuroinflammation, extending the therapeutic window beyond standard acute stroke limits.

A luliconazole pharmaceutical composition utilizes specific organic solvents to enhance drug solubility for external application.

Merges two distinct kinase inhibitors into a single regimen to overcome insufficient efficacy of monotherapy while reducing side effects from high doses.

Self-assembling melphalan hydrogel eliminates carrier materials to increase drug loading and reduce toxic side effects on normal tissues.

Alternative bromodomain inhibitors replace hydroxyurea to increase fetal hemoglobin while reducing myelosuppression and reproductive toxicity.

Merges PPARδ and IGF agonists to address impaired insulin signaling, rescuing neurodegeneration and preserving memory performance.

Dopamine reuptake inhibitors attenuate immunocyte attack on host tissues, improving therapeutic efficacy while reducing side effects from corticosteroids.

Covalent binding to the MEK7 cysteine residue via 4-phenoxypyrimidine derivatives improves kinase selectivity and reduces off-target inhibition.

A sleep supplement composition combines valerian extract, lemon balm extract, and L-theanine in a softgel capsule for oral administration.

Phosphonoalkyl bonds resist hydrolysis by phosphodiesterases, stabilizing 2′3′-cyclic phosphonate dinucleotides for sustained STING activation.

Oxysterols activate Toll-like receptors to induce interferons, reducing viral infectivity without cytotoxicity.

Engineered Cas9 enzymes recognize diverse protospacer adjacent motifs to expand genomic targeting capabilities.

A porous implantable structure releases therapeutic agents into the vitreous humor via diffusion.

A combination ophthalmic gel stabilizes corticosteroid, NSAID, and antibiotic ingredients using cyclodextrin complexation.

Exopolysaccharides from microbial mats restore skin barrier function against environmental stressors.

Specific rhamnogalacturonan-I polysaccharides modulate immune response while maintaining food viscosity by controlling molecular weight and molar ratios.

6-thio-dG induces telomere dysfunction to overcome resistance to MAPK inhibitors and immune checkpoint therapies in melanoma.

Pyrazolo[1,5-a]pyrimidine derivative targets AAK1 activity to address unmet needs in treating schizophrenia and Alzheimer's disease.

Segmented sequencing reactions quantify foreign nucleic acids in heterogeneous biological samples, resolving host genome noise interference.

Morpholino oligonucleotides inhibit VentX expression to expand hematopoietic stem cells, resolving limited ex vivo proliferation effectiveness.

Controlled Rk1 and Rg5 mass ratios in Panax plant extract maximize active ginsenoside content for treating chronic heart failure.

Statistical modeling controls tablet strength and membrane acetyl content to achieve uniform batch quality for low solubility drugs.

Additive layer prevents crystal breakage during folding while maintaining exposure for effective drug transfer.

Fucoxanthin from Phaeodactylum tricornutum extract blocks 5α-reductase to lower dihydrotestosterone levels without synthetic drug side effects.

Neurokinin receptor antagonists prevent pregnancy and achieve chemical castration without triggering cardiovascular disease or hormone-dependent cancer risks.

A progesterone receptor antagonist formulation controls excessive uterine bleeding through competitive receptor binding.

Opacifying agents in the tablet immediately cloud beverages, resolving detection delays associated with coated formulations.

Isolated phytochemicals from Artocarpus hirsutus bark target P. acnes with 2 µg/mL MIC, reducing synthetic antibiotic side effects.

Epinephrine spray formulations deliver rapid drug absorption via mucosal permeation enhancers.

Limonene modifies surface tension to disperse hydrophobic API particles in pharmaceutical suspensions.

LC-ESI-MS/MS with 15N5-CEdG internal standards resolves measurement precision and reliability bottlenecks in diabetic complication monitoring.

Segmented Clozapine pellets with acidic microenvironments maintain therapeutic levels despite pH-dependent solubility challenges.

Compounds with substituted rings target the AKT PH domain to inhibit proliferation while sparing normal cells.

Sequential HPLC, SPE, and SMBC steps isolate pure anti-microbial fractions from crude extracts to resolve purity versus process complexity trade-offs.

BGP15 prevents NASH-induced hepatocellular carcinoma progression by reducing liver fibrosis and ALT levels.

A tacrolimus derivative inhibits peptidyl-prolyl cis/trans isomerase to reduce collagen deposition.